Radisson Hotel Narita
286-0221 Chiba Tomisato- shi Nakaei
650-35 Tokyo, Japan
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Email: cardiology@magnusmeetings.com
October 24-25, 2019 | Tokyo, Japan

Jian Guan

Oral Speaker at Cardiology World Congress 2019- Jian Guan
Jian Guan
University of Auckland, New Zealand
Title : A novel biomarker for cardiovascular conditions

Abstract:

Consistent evidence links insulin-like growth factor (IGF)-1 deficiency to a range of cardiovascular and metabolic disorders including hypertension and stroke. A biomarker for IGF-1 function would be clinical useful for the prognosis of cardiovascular conditions. While plasma IGF-1 is largely inactive due to its high affinity binding of IGF binding protein (IGFBP), cyclic glycine-proline (cGP), an IGF-1 metabolite, can regulate the bioavailability of plasma IGF-1 and improve IGF-1 function by competing with IGF-1 to IGFBP-3 binding1. The relative value of cGP to IGF-1 (cGP/IGF-1 molar ratio) can represent the bioavailable IGF-11-4. 
Our recent clinical observations showed that plasma cGP is low in women with hypertension4 and treatment of cGP normalised the systolic blood pressure in a rat model of high fat diet (HFD)-induced metabolic disorders. 
Plasma cGP was also low in stroke patients at hospital admission (<3 days of stroke). The concentration of cGP was increased and neurological deficits and the disability were gradually improved in next 90 days. The changes of cGP at hospital admission (<3days) was correlated with the scores of NIHSS, mRS and FM-UL 90 days after stroke. Administration of cGP prevents ischemic brain injury though preventing IGF-1 associated vascular injury in rats1. The cGP/IGF-1 ratio at admission may be a potential biomarker for predicting functional recovery in stroke patients. 
In conclusion, low cGP concentrations and low cGP/IGF-1 ratio suggest an impairment of IGF-1 function in hypertension and stroke. The change of plasma cGP concentration and/or cGP/IGF-1 ratio may be a prognostic biomarker for stroke and hypertension and may also provide the guidance for individualizing cGP intervention.

Audience take away:

  • The role for cGP in normalizing IGF-1 function is novel and provides additional insights to IGF-1 research, which aims the normalisation
  • cGP is also nature nutrient and presents in some foods
  • cGP research provides and develops the opportunities to the interventions with plant based supplementation, which has far more advantages in pharmaceutical developed drugs

Biography:

Dr Jian Guan completed the medical degree in China 1982, and gained PhD in Paediatrics from University Auckland, New Zealand in 1996. Jian is neuroscientist with research interests in brain development, aging and functions by evaluating neuroplasticity, vascular remodelling and the interactions of neurons, glial phenotypes and capillaries. Her research specialty includes neurobiology and neuro-pharmacology of IGF-1 and its related peptides, animal modelling, behavioural evaluations, biological and pathological assessments. The discovery of the mechanism of IGF-1 metabolites leads to the investigation of novel biomarker for IGF-1 function. She holds a permanent research position in the Department of Pharmacology and Clinical Pharmacology, the School of Medical Science, FMHS, the University of Auckland.